Crinetics Pharmaceuticals Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Crinetics Pharmaceuticals Inc's ROI in the second quarter of 2026?
Crinetics Pharmaceuticals Inc recorded a cumulative net loss of $-502 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -42.37%.

Within the Healthcare sector 429 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2159 to 3648.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-1.02 %	6.09 %	15.3 %	52.98 %	59.46 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	1,242	1,330	1,041	1,122	1,221
Return On Investment (TTM)	-42.37 %	-42.12 %	-39.7 %	-33.7 %	-30.92 %
CRNX's Overall Ranking	# 3648	# 2159	# 2589	# 3313	# 2247
Seq. Investment Change TTM	0.44 %	0.56 %	-6.65 %	4.98 %	7.65 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-502	-496	-465	-423	-370

CRNX Company Profile >> Back to CRNX Roi Comparisons >> See Annual CRNX Return On Investment

Return On Investment CRNX's Ranking
Within:	No.
Industry	# 172
Sector	# 430
Overall	# 3648

Return On Investment Statistics
High	Average	Low
-21.84 %	-40.23 %	-59.65 %
(Mar 31 2019)		(Jun 30 2023)

News about Crinetics Pharmaceuticals Inc Return on Investment ROI

Crinetics Pharmaceuticals to Unveil Promising Neuroendocrine Tumor Candidates at NANETS Annual Meeting

November 14, 2024

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting Crinetics Pharmaceuticals, a leading innovator in the development of novel therapeutics for endocrine diseases and cancers, is set to debut significant advancements from its pipeline at the 2023 North American Neuroendocrine Tumor Society (NANETS) Annual Meeting. The event will take place from October 19-21, 2023, in Houston, Texas.In a notable highlight, Crinetics will introduce its proprietary nonpeptide drug conjugate platform, which has the potential to revolutionize the treatment landscape for neuroendocrine tumors (NETs). This cutting-edge technology is designed to improve the specificity and efficacy of drug delivery, targeting SST2-expressing tumors with unprecedented precision.

Financial Statements
Crinetics Pharmaceuticals Inc's II. Quarter Investments	$ 1,242 Millions	CRNX's Balance sheet
Crinetics Pharmaceuticals Inc's II. Quarter Income	$ -121 Millions	Quarterly CRNX's Income Statement
CRNX's Income by Division		See CRNX's Income by Division

CRNX Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	1,041	1,375	591	324	335
Y / Y Investment Growth	-24.27 %	132.48 %	82.28 %	-3.15 %	93.7 %
Net Income in Millions	-465	-298	-215	-164	-108
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-44.69 %	-21.7 %	-36.27 %	-50.52 %	-32.13 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
CRNX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for CRNX's Competitors
Subscribers only: Roi for Crinetics Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for CRNX's Customers

Other Ratios
CRNX's Roa	CRNX's Inventory Turnover Ratio	CRNX's Growth Rates	CRNX's Dividend Statistics
	CRNX's Profitability Ratios	CRNX's Asset Turnover Ratio	CRNX's Dividend Growth
CRNX's Roe	CRNX's Valuation Ratios	CRNX's Financial Strength Ratios	CRNX's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-13T23:45:14+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.